Exploring breast carcinogenesis through integrative genomics and epigenomics analyses

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 1959-1968

  Mining, Chin ^a   Mokhtar, Norfilza Mohd ^a   Abdulah, Norlia ^a   Muhamad, Rohaizak ^a   Emran, Nor Aina ^b   Md Ali, Siti Aishah ^a   Harun, Roslan ^a   Jamal, Rahman ^a  

^a DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^b HOSPITAL KUALA LUMPUR   (Malaysia)

Author keywords

Breast cancer; CpG islands; DNA methylation; Epigenetics; Gene expression; Microarray

Indexed keywords

COLLAGEN TYPE 1; PLATELET DERIVED GROWTH FACTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL CYCLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DNA INTEGRATION; DNA METHYLATION; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; FOCAL ADHESION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; HUMAN TISSUE; INTEGRATIVE EPIGENOMICS ANALYSIS; INTEGRATIVE GENOMIC ANALYSIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OVERLAPPING GENE; POLYMERASE CHAIN REACTION; PROTEIN INTERACTION; TUMOR GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; AGED; BREAST TUMOR; CANCER STAGING; CARCINOGENESIS; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; GENOMICS; MIDDLE AGED; PATHOLOGY; PROMOTER REGION;

AGED; BREAST NEOPLASMS; CARCINOGENESIS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC;

EID: 84907221133     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2625     Document Type: Article

References (67)

1. Jones PA: Overview of cancer epigenetics. Semin Hematol 42: S3-S8, 2005.
2. Weber M, Hellmann I, Stadler MB, et al: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39: 457-466, 2007.
3. Davis CD and Uthus EO: DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med (Maywood) 229: 988-995, 2004.
4. Jimenez-Useche I and Yuan C: The effect of DNA CpG methylation on the dynamic conformation of a nucleosome. Biophys J 103: 2502-2512, 2012.
5. Ito K, Barnes PJ and Adcock IM: Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 20: 6891-6903, 2000.
6. Jovanovic J, Ronneberg JA, Tost J and Kristensen V: The epigenetics of breast cancer. Mol Oncol 4: 242-254, 2010.
7. Beisel C and Paro R: Silencing chromatin: Comparing modes and mechanisms. Nat Rev Genet 12: 123-135, 2011.
8. Yang BH, Parkin DM, Cai L and Zhang ZF: Cancer burden and trends in the Asian Pacific Rim region. Asian Pac J Cancer Prev 5: 96-117, 2004.
9. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
10. Z hang X, Sun Q, Shan M, et al: Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers. PloS one 8: E53931, 2013.
11. Bubnov V, Moskalev E, Petrovskiy Y, Bauer A, Hoheisel J and Zaporozhan V: Hypermethylation of TUSC5 genes in breast cancer tissue. Exp Oncol 34: 370-372, 2012.
12. Heyn H, Carmona FJ, Gomez A, et al: DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis 34: 102-108, 2013.
13. Faryna M, Konermann C, Aulmann S, et al: Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J 26: 4937-4950, 2012.
14. Lo Nigro C, Monteverde M, Lee S, et al: NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer 107: 75-83, 2012.
15. Kim MS, Lee J, Oh T, et al: Genome-wide identification of OTP gene as a novel methylation marker of breast cancer. Oncol Rep 27: 1681-1688, 2012.
16. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ and Futscher BW: Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res 68: 8616-8625, 2008.
17. Coolen MW, Stirzaker C, Song JZ, et al: Consolidation of the cancer genome into domains of repressive chromatin by longrange epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 12: 235-246, 2010.
18. Novak P, Jensen T, Oshiro MM, et al: Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res 66: 10664-10670, 2006.
19. Ehrlich M: DNA methylation in cancer: Too much, but also too little. Oncogene 21: 5400-5413, 2002.
20. Costa FF, Paixao VA, Cavalher FP, et al: SATR-1 hypomethylation is a common and early event in breast cancer. Cancer Genet Cytogenet 165: 135-143, 2006.
21. Berman BP, Weisenberger DJ, Aman JF, et al: Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-Associated domains. Nat Genet 44: 40-46, 2012.
22. Li M, Balch C, Montgomery JS, et al: Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2: 34, 2009.
23. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.
24. Sun Z, Asmann YW, Kalari KR, et al: Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. PloS one 6: E17490, 2011.
25. Mokhtar NM, Ramzi NH, Yin-Ling W, Rose IM, Hatta Mohd Dali AZ and Jamal R: Laser capture microdissection with genome-wide expression profiling displayed gene expression signatures in endometrioid endometrial cancer. Cancer Invest 30: 156-164, 2012.
26. Bibikova M, Le J, Barnes B, et al: Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 1: 177-200, 2009.
27. Eads CA, Danenberg KD, Kawakami K, et al: MethyLight: A high-Yhroughput assay to measure DNA methylation. Nucleic Acids Res 28: E32, 2000.
28. Mascolo M, Siano M, Ilardi G, et al: Epigenetic disregulation in oral cancer. Int J Mol Sci 13: 2331-2353, 2012.
29. Qu Z, Fu J, Yan P, Hu J, Cheng SY and Xiao G: Epigenetic repression of PDZ-LIM domain-containing protein 2: Implications for the biology and treatment of breast cancer. J Biol Chem 285: 11786-11792, 2010.
30. Yano M, Toyooka S, Tsukuda K, et al: Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 113: 59-66, 2005.
31. Jeschke J, Van Neste L, Glockner SC, et al: Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 7: 701-709, 2012.
32. Rhodes DR, Ateeq B, Cao Q, et al: AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA 106: 10284-10289, 2009.
33. Bieche I, Chavey C, Andrieu C, et al: CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 14: 1039-1052, 2007.
34. Evron E, Umbricht CB, Korz D, et al: Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 61: 2782-2787, 2001.
35. Veeck J, Bektas N, Hartmann A, et al: Wnt signalling in human breast cancer: Expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res: R82, 2008.
36. Cao XC, Zhang WR, Cao WF, et al: Aquaporin3 is required for FGF-2-induced migration of human breast cancers. PloS one 8: E56735, 2013.
37. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros D and Diamandis EP: Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol 26: 324-336, 2005.
38. Fernandez SV, Snider KE, Wu YZ, Russo IH, Plass C and Russo J: DNA methylation changes in a human cell model of breast cancer progression. Mutat Res 688: 28-35, 2010.
39. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR and Milner PG: Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74: 1584-1590, 1994.
40. Perez-Pinera P, Garcia-Suarez O, Menendez-Rodriguez P, et al: The receptor protein tyrosine phosphatase (RPTP)β/? is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun 362: 5-10, 2007.
41. Lo PK, Mehrotra J, D'Costa A, et al: Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. Cancer Biol Ther 5: 281-286, 2006.
42. Ko CD, Kim JS, Ko BG, et al: The meaning of the c-kit protooncogene product in malignant transformation in human mammary epithelium. Clin Exp Metastasis 20: 593-597, 2003.
43. Stein T, Cosimo E, Yu X, et al: Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol 177: 2323-2333, 2010.
44. Dote H, Toyooka S, Tsukuda K, et al: Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res 10: 2082-2089, 2004.
45. Hoang BH, Kubo T, Healey JH, et al: Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 64: 2734-2739, 2004.
46. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW and Band V: The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58: 4782-4786, 1998.
47. Huang HE, Chin SF, Ginestier C, et al: A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res 64: 6840-6844, 2004.
48. Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V and Lianidou ES: Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Ann Oncol 20: 1020-1025, 2009.
49. Veeck J, Niederacher D, An H, et al: Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25: 3479-3488, 2006.
50. Dahl E, Veeck J, An H, et al: Epigenetic inactivation of the WNT antagonist SFRP1 in breast cancer. Verh Dtsch Ges Pathol 89: 169-177, 2005 (in German).
51. Xie D, Gore C, Zhou J, et al: DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci USA 106: 19878-19883, 2009.
52. Z hang X, Li N, Li X, et al: Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma. J Gastroenterol Hepatol 27: 1117-1125, 2012.
53. Henderson DJ, Phillips HM and Chaudhry B: Vang-like 2 and noncanonical Wnt signaling in outflow tract development. Trends Cardiovasc Med 16: 38-45, 2006.
54. Cadigan KM and Nusse R: Wnt signaling: A common theme in animal development. Genes Dev 11: 3286-3305, 1997.
55. Z hang J, Liu J, Li X, et al: The physical and functional interaction of NDRG2 with MSP58 in cells. Biochem Biophys Res Commun 352: 6-11, 2007.
56. Z heng J, Liu Q, Li Y, et al: NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells. Asian Pac J Cancer Prev 11: 1817-1821, 2010.
57. Euhus DM, Bu D, Milchgrub S, et al: DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 17: 1051-1059, 2008.
58. Bikfalvi A, Klein S, Pintucci G and Rifkin DB: Biological roles of fibroblast growth factor-2. Endocr Rev 18: 26-45, 1997.
59. Loss LA, Sadanandam A, Durinck S, et al: Prediction of epigenetically regulated genes in breast cancer cell lines. BMC Bioinformatics 11: 305, 2010.
60. Mazouni C, Arun B, Andre F, et al: Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer 99: 68-71, 2008.
61. Summers KM, Bokil NJ, Baisden JM, et al: Experimental and bioinformatic characterisation of the promoter region of the Marfan syndrome gene, FBN1. Genomics 94: 233-240, 2009.
62. Sengupta PK, Smith EM, Kim K, Murnane MJ and Smith BD: DNA hypermethylation near the transcription start site of collagen a2(I) gene occurs in both cancer cell lines and primary colorectal cancers. Cancer Res 63: 1789-1797, 2003.
63. Ross DT and Perou CM: A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers 17: 99-109, 2001.
64. Clark MB, Johnston RL, Inostroza-Ponta M, et al: Genome-wide analysis of long noncoding RNA stability. Genome Res 22: 885-898, 2012.
65. Kumar R, Gururaj AE and Barnes CJ: P21-Activated kinases in cancer. Nat Rev Cancer 6: 459-471, 2006.
66. Dohi O, Takada H, Wakabayashi N, et al: Epigenetic silencing of RELN in gastric cancer. Int J Oncol 36: 85-92, 2010.
67. Bornstein P: Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal 3: 189-200, 2009.